Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAMES: Gut Microbiome in Multi-ethnic Singaporeans
NCT02893709Completed
- Sponsor
- Changi General Hospital
- Start
- Jun 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of omeprazole in gastroesophageal reflux disease (GERD), sponsored by Changi General Hospital. Primary endpoints: Change in species diversity after omeprazole treatment at 2 weeks, Emergence of signature taxa after omeprazole treatment at 2 weeks and 2 more. Started Jun 2015; status: completed.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02893709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893709.